These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
284 related articles for article (PubMed ID: 23788581)
1. Controlled local delivery of CTLA-4 blocking antibody induces CD8+ T-cell-dependent tumor eradication and decreases risk of toxic side effects. Fransen MF; van der Sluis TC; Ossendorp F; Arens R; Melief CJ Clin Cancer Res; 2013 Oct; 19(19):5381-9. PubMed ID: 23788581 [TBL] [Abstract][Full Text] [Related]
2. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs. Allard B; Pommey S; Smyth MJ; Stagg J Clin Cancer Res; 2013 Oct; 19(20):5626-35. PubMed ID: 23983257 [TBL] [Abstract][Full Text] [Related]
3. Enhancement of antitumor immunity by combining anti-cytotoxic T lymphocyte antigen-4 antibodies and cryotreated tumor lysate-pulsed dendritic cells in murine osteosarcoma. Kawano M; Itonaga I; Iwasaki T; Tsumura H Oncol Rep; 2013 Mar; 29(3):1001-6. PubMed ID: 23291864 [TBL] [Abstract][Full Text] [Related]
4. Local activation of CD8 T cells and systemic tumor eradication without toxicity via slow release and local delivery of agonistic CD40 antibody. Fransen MF; Sluijter M; Morreau H; Arens R; Melief CJ Clin Cancer Res; 2011 Apr; 17(8):2270-80. PubMed ID: 21389097 [TBL] [Abstract][Full Text] [Related]
5. Monotherapeutically nonactive CTLA-4 blockade results in greatly enhanced antitumor effects when combined with tumor-targeted superantigens in a B16 melanoma model. Sundstedt A; Celander M; Eriksson H; Törngren M; Hedlund G J Immunother; 2012 May; 35(4):344-53. PubMed ID: 22495392 [TBL] [Abstract][Full Text] [Related]
6. Breaking immune tolerance by targeting CD25+ regulatory T cells is essential for the anti-tumor effect of the CTLA-4 blockade in an HLA-DR transgenic mouse model of prostate cancer. Klyushnenkova EN; Riabov VB; Kouiavskaia DV; Wietsma A; Zhan M; Alexander RB Prostate; 2014 Oct; 74(14):1423-32. PubMed ID: 25111463 [TBL] [Abstract][Full Text] [Related]
7. Intratumoral anti-CTLA-4 therapy: enhancing efficacy while avoiding toxicity. Marabelle A; Kohrt H; Levy R Clin Cancer Res; 2013 Oct; 19(19):5261-3. PubMed ID: 23965900 [TBL] [Abstract][Full Text] [Related]
8. CTLA-4 blockade enhances antitumor immunity of intratumoral injection of immature dendritic cells into irradiated tumor in a mouse colon cancer model. Son CH; Bae JH; Shin DY; Lee HR; Choi YJ; Jo WS; Ho Jung M; Kang CD; Yang K; Park YS J Immunother; 2014 Jan; 37(1):1-7. PubMed ID: 24316550 [TBL] [Abstract][Full Text] [Related]
9. Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. John LB; Devaud C; Duong CP; Yong CS; Beavis PA; Haynes NM; Chow MT; Smyth MJ; Kershaw MH; Darcy PK Clin Cancer Res; 2013 Oct; 19(20):5636-46. PubMed ID: 23873688 [TBL] [Abstract][Full Text] [Related]
11. CTLA-4 Limits Anti-CD20-Mediated Tumor Regression. Ren Z; Guo J; Liao J; Luan Y; Liu Z; Sun Z; Liu X; Liang Y; Peng H; Fu YX Clin Cancer Res; 2017 Jan; 23(1):193-203. PubMed ID: 27354469 [TBL] [Abstract][Full Text] [Related]
12. Immune checkpoint proteins: a new therapeutic paradigm for cancer--preclinical background: CTLA-4 and PD-1 blockade. Weber J Semin Oncol; 2010 Oct; 37(5):430-9. PubMed ID: 21074057 [TBL] [Abstract][Full Text] [Related]
13. Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals. Mitsui J; Nishikawa H; Muraoka D; Wang L; Noguchi T; Sato E; Kondo S; Allison JP; Sakaguchi S; Old LJ; Kato T; Shiku H Clin Cancer Res; 2010 May; 16(10):2781-91. PubMed ID: 20460483 [TBL] [Abstract][Full Text] [Related]
14. CTLA-4 blockade expands infiltrating T cells and inhibits cancer cell repopulation during the intervals of chemotherapy in murine mesothelioma. Wu L; Yun Z; Tagawa T; Rey-McIntyre K; de Perrot M Mol Cancer Ther; 2012 Aug; 11(8):1809-19. PubMed ID: 22584123 [TBL] [Abstract][Full Text] [Related]
15. A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy. Du X; Tang F; Liu M; Su J; Zhang Y; Wu W; Devenport M; Lazarski CA; Zhang P; Wang X; Ye P; Wang C; Hwang E; Zhu T; Xu T; Zheng P; Liu Y Cell Res; 2018 Apr; 28(4):416-432. PubMed ID: 29472691 [TBL] [Abstract][Full Text] [Related]
16. Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4. Dias JD; Hemminki O; Diaconu I; Hirvinen M; Bonetti A; Guse K; Escutenaire S; Kanerva A; Pesonen S; Löskog A; Cerullo V; Hemminki A Gene Ther; 2012 Oct; 19(10):988-98. PubMed ID: 22071969 [TBL] [Abstract][Full Text] [Related]
17. Antibody Blockade of Semaphorin 4D Promotes Immune Infiltration into Tumor and Enhances Response to Other Immunomodulatory Therapies. Evans EE; Jonason AS; Bussler H; Torno S; Veeraraghavan J; Reilly C; Doherty MA; Seils J; Winter LA; Mallow C; Kirk R; Howell A; Giralico S; Scrivens M; Klimatcheva K; Fisher TL; Bowers WJ; Paris M; Smith ES; Zauderer M Cancer Immunol Res; 2015 Jun; 3(6):689-701. PubMed ID: 25614511 [TBL] [Abstract][Full Text] [Related]
18. Potent induction of tumor immunity by combining tumor cryoablation with anti-CTLA-4 therapy. Waitz R; Solomon SB; Petre EN; Trumble AE; Fassò M; Norton L; Allison JP Cancer Res; 2012 Jan; 72(2):430-9. PubMed ID: 22108823 [TBL] [Abstract][Full Text] [Related]
19. Murine bone marrow chimeras developing autoimmunity after CTLA-4-blockade show an expansion of T regulatory cells with an activated cytokine profile. De Somer L; Fevery S; Bullens DM; Rutgeerts O; Lenaerts C; Mathieu C; Boon L; Kasran A; Waer M; Billiau AD Immunol Lett; 2010 Sep; 133(1):49-53. PubMed ID: 20600326 [TBL] [Abstract][Full Text] [Related]